Drugs / Ethionamide
Ethionamide
also known as
1314 TH · BAYER 5312 · Ethionamidum · Etionamida · Nizotin · NSC-255115 · Trecator · Trecator-sc
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TRECATOR | — | 1965-04-30 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07350174 | Mar 2026 → Mar 2028 expected | meningeal tuberculosis | BioVersys AG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06748937 | Mar 2025 → Mar 2026 overdue | pulmonary tuberculosis | TASK Applied Science | Recruiting | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
| Phase 2 | NCT05473195 | Dec 2022 → Apr 2024 | primary pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02454205 | Nov 2015 → Dec 2020 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00000796 | ? → Oct 1998 | HIV infectious disease, pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02975570 Comparator | Aug 2017 → Aug 2021 | multidrug-resistant tuberculosis | Boston University | Withdrawn | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethionamide | “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗9“Alpe375 (alpibectir (30 mg/day), ethionamide (375 mg/day))” NCT07350174 ↗ “streptomycin, ethionamide, prothionamide, cycloserine” NCT03237182 ↗ “ethionamide (or prothionamide)” NCT02975570 ↗ “Ethionamide” NCT02099240 ↗ |
| Known as | 1314 TH | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | BAYER 5312 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | Ethionamidum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | Etionamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | Nizotin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | NSC-255115 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | Trecator | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Known as | Trecator-sc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1441 ↗ |
| Modality | Small molecule | — CHEMBL1441 ↗ |
| Route | Oral | “Participants will receive six to nine months of oral: Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times...” NCT02454205 ↗ |